NCT07753642Not yet recruitingPhase 2
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
A Phase II, Prospective, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golidocitinib Combined With an Anthracycline-Based Regimen as First-Line Treatment for Patients With Nodal T-follicular Helper (TFH) Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with previously untreated nodal T-follicular helper (TFH) cell lymphoma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- First submitted
- 3 Aug 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Sun Yat-sen University
- NCT number
- NCT07753642
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 47
- From 15 Aug 2026 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving potent CYP3A inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants.
- Patients who have received systemic corticosteroids or other immunosuppressive therapy within 14 days before the start of study treatment.
Other illness
- Hemophagocytic syndrome.
- Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.
- Patients with active infections, including tuberculosis, HIV infection, active hepatitis B, or active hepatitis C.
- Patients with severe or uncontrolled cardiovascular disease.
- Patients with a history of interstitial lung disease, except for asymptomatic radiation-induced interstitial lung disease.
- Patients with gastrointestinal conditions that may interfere with oral administration or drug absorption.
- Patients with known hypersensitivity to golidocitinib or its excipients.
Other
- Central nervous system or meningeal involvement by lymphoma.
- Pregnant or breastfeeding women and participants of childbearing potential unwilling to use effective contraception.
- Patients considered unsuitable for participation by the investigator.
Who the study is looking for
- Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.
- Previously untreated with systemic anti-lymphoma therapy.
- Age ≥18 and \<75 years.
- At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
- An expected survival time of more than 12 weeks.
- An ECOG performance status score of 0-1.
- Adequate organ and bone marrow function.
- Provision of written informed consent and willingness to comply with all study procedures.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.